(Q43693344)

English

Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).

scientific article published in July 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus). (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Common Marmoset

0 references

1 reference

based on heuristic

inferred from title

author name string

Maratos EC

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Jackson MJ

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Pearce RK

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Jenner P

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

language of work or name

0 references

publication date

1 July 2001

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Movement Disorders

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

631-641

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

"Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Pergolide in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Dopamine agonists in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Is levodopa toxic to human substantia nigra?

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Levodopa neurotoxicity: experimental studies versus clinical relevance

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Levodopa-induced dyskinesia: review, observations, and speculations

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Does combined levodopa and bromocriptine therapy in Parkinson's disease prevent late motor complications?

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Long-term follow-up of early dopa treatment in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Double-blind controlled study of pergolide mesylate in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Ropinirole without levodopa in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

An Australian multicentre open label study of pergolide as an adjunct to levodopa in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Effects of Chronic Levodopa Therapy on Dopa Pharmacokinetics

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Is levodopa toxic?

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Relationship between levodopa concentration, dyskinesias, and motor effect in parkinsonian patients: a 3-year follow-up study

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Young onset Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.1149

21 January 2018

Identifiers

10.1002/MDS.1149

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43693344&oldid=2102625098"